Replies to post #224282 on Biotech Values

[DewDiligence]

ASMB—…I've never seen a lead drug already being developed over so many times so early in its development.

The backup HBV compounds aren’t merely tweaks of the lead compound (ABI-H0731), but rather have a different chemical structure from the lead compound and from each other. This is nevertheless an odd development program that does not inspire confidence from investors, as you noted.

[DewDiligence]

ASMB webcast Monday re phase-2a data:

https://finance.yahoo.com/news/assembly-biosciences-presents-data-highlighting-110500800.html